InvestorsHub Logo

Esa

Followers 11
Posts 416
Boards Moderated 0
Alias Born 02/21/2011

Esa

Re: None

Monday, 12/02/2019 10:02:44 AM

Monday, December 02, 2019 10:02:44 AM

Post# of 3612
In October, Cassava Sciences announced that results of its Phase 2a study of PTI-125 were selected for a late-breaking oral presentation by the 12th International Conference on Clinical Trials on Alzheimer’s Disease (CTAD), which takes place December 4-7th, 2019
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SAVA News